论文部分内容阅读
近年来研制出的许多新抗癌药,已在临床上应用,这类药剂化合物的功能已在某种程度上确定。努力使研制出的药物既有抗肿瘤作用,又具有安全性。对于扩大药物的抗肿瘤范围及减少对原始化合物的耐药性方面也应给予关心。通过研究,确实减轻了一些副作用,但很难得到有更好抗肿瘤性质的药物。日本的特点是对5-FU有关的化合物研究较多。近年来对阿霉素(ADM)和顺铂的有关化合物也积极进行研究。
Many new anticancer drugs that have been developed in recent years have been used clinically. The function of such pharmaceutical compounds has been determined to some extent. Efforts have been made to develop drugs that are both anti-tumor and safe. It should also be concerned about expanding the anti-tumor range of drugs and reducing the resistance to the original compounds. Through research, some side effects have indeed been alleviated, but it is difficult to obtain drugs with better anti-tumor properties. Japan is characterized by more research on 5-FU-related compounds. In recent years, studies on related compounds of adriamycin (ADM) and cisplatin have also been actively conducted.